pharmaphorum September 8, 2025
NRG Therapeutics has secured the funding it needs to take a potentially first-in-class therapy for neurodegenerative diseases from preclinical development into human testing.
The Stevenage, UK-based biotech has closed a £50 million ($67 million) Series B – three years after its £16 million first round – which it said would give it the resources needed to advance lead candidate NRG5051 through initial proof-of-concept (PoC) testing in amyotrophic lateral sclerosis (ALS, also known as motor neurone disease or MND), as well as Parkinson’s disease.
NRG’s R&D pipeline is focused on brain-penetrant, small-molecule inhibitors of the mitochondrial permeability transition pore (mPTP), which forms in the inner membrane of mitochondria – the energy-producing structure in the cell – leading to disruption of their...
Today's Sponsors
Today's Sponsor